What treatments have been studied to reduce the risk of vascular events in patients with cystathionine-synthase deficiency?
A study of treatment of severe hyperhomocysteine performed in Australia, the Netherlands, and Ireland on patients who had cystathionine-synthase deficiency (mean age, 27.8 years; range, 2.5 70 years) supported a dramatic reduction of risk of vascular events relative to a historical cohort study (RR, 2).